New guideline for screening mammography for women 40 to 49 years of age

April 02, 2007

PHILADELPHIA, April 3, 2007 -- The American College of Physicians (ACP) today released a new clinical practice guideline for screening mammography for women 40 to 49 years of age. The guideline, a background article, an editorial, and a patient summary appear in today's issue of Annals of Internal Medicine, published by ACP.

ACP developed the guideline to present the available evidence for screening mammography to physicians and women between the ages of 40 and 49 and to increase their understanding of the benefits and risks of screening mammography in women within this age group.

"We designed our screening mammography guideline based on scientific evidence," said Lynne Kirk, MD, FACP, President of ACP. "It will empower women between the ages of 40 and 49 to become part of the decision-making process and to encourage them to discuss with their physicians the benefits and risks of mammograms."

The guideline states that, according to the evidence studied, breast cancer risk is not evenly distributed in women between the ages of 40 and 49. Thus the benefits of screening mammography are not uniformly applicable in women in this age group. Therefore, women 40 to 49 years of age need to take into account their level of risk and the possible benefits and harms of screening mammography.

The main benefit of screening mammography is a decrease in breast cancer mortality. However, the risks associated with screening mammography include false-positive results, possible treatment for lesions that would not have become clinically significant, and radiation exposure.

"It is important to tailor the decision of screening mammography by discussing the benefits and risks with a woman, addressing her concerns, and making it a joint decision between her and her physician," said lead author Amir Qaseem, MD, PhD, MHA, Senior Medical Associate in the Clinical Programs and Quality of Care Department of the Medical Education and Publishing Division at ACP.

The guideline makes four recommendations for women between the ages of 40 and 49:

"If a woman between the ages of 40 and 49 decides not to have a mammogram, she and her doctor should re-address the issue every one to two years," Kirk added.

In a separate editorial, Joann Elmore, MD, MPH, and John Choe, MD, MPRH, wrote: "In the face of continuing controversy about the evidence, our priority now should be to help women make informed decisions."

ACP's clinical guidelines are developed in an explicit, rigorous process based on extensive review of available scientific evidence. They are considered "evidence-based" rather than "expert-opinion" or consensus guidelines. In addition to publications from the original mammography trials, ACP reviewed 117 studies to evaluate the evidence about the risks and benefits of mammography screening for women between the ages of 40 and 49.
-end-
Annals of Internal Medicine is one of the most widely cited peer-reviewed medical journals in the world. The journal has been published for 80 years and accepts only 7 percent of the original research studies submitted for publication.

The American College of Physicians is the largest medical specialty organization and the second-largest physician group in the United States. ACP members include 120,000 internal medicine physicians (internists), related subspecialists, and medical students. Internists specialize in the prevention, detection and treatment of illness in adults.

American College of Physicians

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.